Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 12

Results For "inflammatory"

198 News Found

2654 compounds screened for different activities for GPCR profiling: Dr Jitendra Singh
Policy | March 16, 2023

2654 compounds screened for different activities for GPCR profiling: Dr Jitendra Singh

MoES have identified a potent Anti-cancer molecule named GS/IICT5/6


Zydus receives final approval from the USFDA for Erythromycin Tablets
Drug Approval | March 10, 2023

Zydus receives final approval from the USFDA for Erythromycin Tablets

Erythromycin Tablets USP, 250 mg and 500 mg are used to prevent and treat infections in many different parts of the body


FDA approves Pfizer's supplemental new drug application for CIBINQO
Drug Approval | February 14, 2023

FDA approves Pfizer's supplemental new drug application for CIBINQO

Label expansion for CIBINQO provides new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis


Janssen and Eli Lilly collaboration to address lack of pediatric therapies could rescue mirikizumab program, says GlobalData
News | February 06, 2023

Janssen and Eli Lilly collaboration to address lack of pediatric therapies could rescue mirikizumab program, says GlobalData

The agreement between Eli Lilly and Janssen was established to allow the two companies to share resources for the goal of accelerating the evaluation of the respective companies’ assets, mirikizumab and Tremfya (guselkumab).


ExeGi Pharma gets clearance of IND application for EXE-346 a Live biotherapeutic biologic drug
Drug Approval | January 30, 2023

ExeGi Pharma gets clearance of IND application for EXE-346 a Live biotherapeutic biologic drug

This clearance allows the company to initiate a clinical trial for patients with an ileal pouch-anal anastomosis


Aarti Drugs Q3 FY23 revenue grows 4%
News | January 28, 2023

Aarti Drugs Q3 FY23 revenue grows 4%

Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY


Yaral Pharma launches diclofenac epolamine topical system 1.3%
News | January 05, 2023

Yaral Pharma launches diclofenac epolamine topical system 1.3%

Diclofenac epolamine topical system 1.3% offers patients a non-opioid topical treatment


Biocon initiates clinical study of Itolizumab for ulcerative colitis in India
Clinical Trials | December 15, 2022

Biocon initiates clinical study of Itolizumab for ulcerative colitis in India

This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study


Alembic receives USFDA final Approval for Desonide Cream
Drug Approval | December 12, 2022

Alembic receives USFDA final Approval for Desonide Cream

Desonide Cream, 0.05%, has an estimated market size of US $12 million for twelve months ending Sep 2022 according to IQVIA


AstraZeneca updates on the MESSINA Phase III trial for Fasenra in eosinophilic esophagitis
Clinical Trials | October 26, 2022

AstraZeneca updates on the MESSINA Phase III trial for Fasenra in eosinophilic esophagitis

High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints.